Trimetazidine

This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (February 2022) (Learn how and when to remove this message)

Trimetazidine

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	C01EB15 (WHO)
Legal status
Legal status	UK: Controlled Drug
Pharmacokinetic data
Bioavailability	completely absorbed at around 5 hours, steady state is reached by 60th hour
Protein binding	low (16%)
Metabolism	minimal
Elimination half-life	7 to 12 hours
Excretion	mainly renal (unchanged), exposure is increased in renal impairment – on average by four-fold in subjects with severe renal impairment (CrCl <30 ml/min)
Identifiers
IUPAC name 1-(2,3,4-trimethoxybenzyl)piperazine
CAS Number	5011-34-7 N
PubChem CID	21109
ChemSpider	19853 Y
UNII	N9A0A0R9S8
ChEMBL	ChEMBL203266 Y
CompTox Dashboard (EPA)	DTXSID2048531
ECHA InfoCard	100.023.355
Chemical and physical data
Formula	C14H22N2O3
Molar mass	266.341 g·mol−1
3D model (JSmol)	Interactive image
SMILES O(c1ccc(c(OC)c1OC)CN2CCNCC2)C
InChI InChI=1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3 Y Key:UHWVSEOVJBQKBE-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug sold under many brand names for angina pectoris (chest pain associated with impaired blood flow to the heart).^[1] Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves the heart muscle's ability to use glucose as a fuel by inhibiting its use of fatty acid metabolism. It has become controversial for its use as a performance-enhancing drug, with several scandals involving its use erupting at successive Olympic games.